The Society of Gynecologic Oncology of Canada

https://www.gyneoncology.ca

Contact us

This is a past event. Registration is closed. View other The Society of Gynecologic Oncology of Canada events.

Event Details

Registration for the GOC Symposium on Molecular Biology for Gynecologic Cancers is now closed! You can still register to GOC's 22nd Continuing Professional Development Meetinguntil 6PM EST today.


Are you registered for the symposium? Go to the email from SpotMe (noreply@spotme.com) that was previously sent to you to give you access to the event. Please access the event platform to get the zoom link and to see the agenda in your own time zone. Once on the platform, click on today's date and on the first session to get the zoom link which is at the bottom of the page. Note that your web access link is unique and cannot be shared.

Questions? Send us an email at enquiry@gyneoncology.ca.




The objective for this symposium is to discuss current, relevant, molecular and cell biology discoveries, highlighting how these insights impact our understanding of the pathogenesis and treatment of cancer. The goal is to provide engaging and enlightening presentations geared to clinicians with a view to broaden their knowledge of the basic science of cancer as it relates to the prevention, detection and treatment of cancer. Key historical advances that have shaped our approach to cancer are of interest. This year, we are highlighting mechanisms of therapeutic resistance and promising molecular targets in gynecologic cancers.


This is a virtual meeting. Please note that all times in the agenda on this site are in PST.

Agenda

April 27, 2022

Main Schedule

2:00 PM
Introduction
Melica Brodeur (Research fellow at Memorial Sloan Kettering Cancer Center)
Taymaa May (Gynecologic Oncologist at Princess Margaret Cancer Center)
2:10 PM - 2:40 PM
Exploiting Homologous Recombination Deficiency in Ovarian Cancer
The goal of this session is to discuss the implications of HRD in Ovarian cancer to help understand mechanisms of primary and acquired resistance to PARPi.
Kirsten Timms PhD (Senior VP Biomarker Discovery at Myriad Genetics Inc)
Mark Carey (Clinical Professor at Vancouver General Hospital)
2:40 PM - 3:10 PM
The Molecular Implications of HR in Endometrial Cancer: TP(53) or NOT TP(53) - is that the question?
The goal of this session is to review HRD in Endometrial Cancer and highlight its relationship to the molecular classification of endometrial cancer and the use of PARPi as a treatment.
Britta Weigelt (Associate Attending Molecular Geneticist, Department of Pathology and Laboratory Medicine Director, Gynecology DMT Research Laboratory at Memorial Sloan Kettering Cancer Center)
3:10 PM - 3:50 PM
What's Neu with Her2: A Target of Promise in Endometrial and Ovarian cancers?
The goal of this session is to provide important background information for participants that will facilitate the understanding of HER2 as a promising therapeutic target in endometrial and ovarian cancers.
Amanda Fader (Vice Chair of Gynecologic Surgical Operations at Johns Hopkins Health System)
3:50 PM - 4:00 PM
Wrap Up Discussion
Mark Carey (Clinical Professor at Vancouver General Hospital)
Melica Brodeur (Research fellow at Memorial Sloan Kettering Cancer Center)

Speakers

Melica Brodeur (Research fellow at Memorial Sloan Kettering Cancer Center)

Melica Brodeur

Research fellow at Memorial Sloan Kettering Cancer Center

Mark Carey (Clinical Professor at Vancouver General Hospital)

Mark Carey

Clinical Professor at Vancouver General Hospital

Amanda Fader (Vice Chair of Gynecologic Surgical Operations at Johns Hopkins Health System)

Amanda Fader

Vice Chair of Gynecologic Surgical Operations at Johns Hopkins Health System

Taymaa May (Gynecologic Oncologist at Princess Margaret Cancer Center)

Taymaa May

Gynecologic Oncologist at Princess Margaret Cancer Center

Kirsten Timms PhD (Senior VP Biomarker Discovery at Myriad Genetics Inc)

Kirsten Timms PhD

Senior VP Biomarker Discovery at Myriad Genetics Inc

Britta Weigelt (Associate Attending Molecular Geneticist, Department of Pathology and Laboratory Medicine Director, Gynecology DMT Research Laboratory at Memorial Sloan Kettering Cancer Center)

Britta Weigelt

Associate Attending Molecular Geneticist, Department of Pathology and Laboratory Medicine Director, Gynecology DMT Research Laboratory at Memorial Sloan Kettering Cancer Center

Planning Committee

Members of the course planning committee

MARK CAREY

CHAIR


He completed his medical degree and Obstetrics & Gynaecology residency at the University of Western Ontario, a fellowship in Gynaecologic Oncology at the University of Toronto and McMaster University, and a research fellowship in the Department of Systems Biology at the University of Texas, MD Anderson Cancer Centre. He runs his research program through OvCaRe and has funding through private donations and his medical corporation to support his laboratory staff. He is Co-Investigator on a recent grant award from the Cancer Research Society with Dr. Cheng-Han Lee, and has done contract research for investigational drug testing. His laboratory has been supported as well by research funds from Dr. Dianne Miller and the Division of Gyn Oncology, the BC Cancer Agency, the Carraresi Foundation OvCaRe Research Grant, and VGH and UBC Hospital Foundations. Mark regularly supervises PhD and MSc candidates and is a member of the department's Research Advisory Committee.


Conflict of Interest Form (coming soon!)

LILLY MCLELLAN

MEMBER


Conflict of Interest Form (coming soon!)

TAYMAA MAY 

MEMBER


Dr. Taymaa May received her medical degree from McGill University in Montreal and went on to complete post-graduate training in Obstetrics and Gynecology at the University of Toronto. During her residency, Dr. May completed the Clinician Investigator Program and received a Master's of Science degree from the Institute of Medical Sciences at the University of Toronto. Following residency, Dr. Taymaa May completed a 3-year fellowship in Gynecologic Oncology at Brigham and Women's Hospital/ Dana Farber Cancer Institute, Harvard Medical School in Boston, MA. 

Dr. Taymaa May is a surgical scientist at the University Health Network and an Assistant Professor at the University of Toronto. Dr. May has clinical training in the medical management of women with gynecological malignancies and surgical training in complex oncologic surgeries including pelvic, abdominal, laparoscopic and robotic surgery. Her research interests are in translational science and clinical trials in the field of ovarian cancer.



Conflict of Interest Form (coming soon!)

VANESSA CARLSON

MEMBER



Conflict of Interest Form (coming soon!)

MELICA BRODEUR

MEMBER



Conflict of Interest Form (coming soon!)

MARTA LLAURADO

MEMBER


Conflict of Interest Form (coming soon!)

PATTI POWER

MEMBER / CHAIR, CPD PLANNING COMMITTEE


Dr. Power is the Divisional Chief of Gynecologic Oncology within Eastern Health and is a MUN Associate Professor within the Women's Health program. She is a graduate of Memorial's Medical School and completed her fellowship in Gynecologic Oncology in Calgary as well as a Diploma in Clinical Epidemiology at Memorial. She has been an active mentor in the Obstetrics and Gynecology program at MUN for many years, is an active member of the Residency Training Program for Obstetrics and Gynecology and is the Competency by Design Lead for that program. She has been a Royal College examiner for Obstetrics and Gynecology for the past 5 years and has now joined the Gynecologic Oncology Royal College Nucleus Committee. She is past president of The Society of Canadian Colposcopists and previous chair of the Subspecialties Committee of Academic Professionals in Obstetrics and Gynecology (APOG) of Canada. She is also an active member of the Scientific Advisory Committee for the H. Bliss Murphy Cancer Center. She has a special interest in student well-being and looks forward to positively contributing to the success of Memorial's undergraduate and postgraduate medical students. 


Conflict of Interest Form (coming soon!)

ALON ALTMAN

EXECUTIVE REPRESENTATIVE / PRESIDENT-ELECT


Dr. Alon Altman is a professor of obstetrics, gynecology and reproductive sciences at the Rady Faculty of Health Sceinces. He is also a gynecologic oncologist at the Health Sciences Centre/Cancercare Manitoba.

He has a strong interest in undergraduate/postgraduate education and research.

Dr. Altman is the president elect for the Society of Gynecologic Oncology of Canada (GOC), the program director for the department of Obstetrics and Gynecology, chair of the University Medical Group (UMG), vice chair for the Medical Management Safety Committee (MMSC) at CancerCare Manitoba, the current Gynecologic oncology track lead for the FIGO 2021 Scientific planning committee and the previous co-chair of the Canadian Obstetrics and Gynecology Review program (COGRP).

He is actively involved in multiple university, national and international committees.


Conflict of Interest Form (coming soon!)

MARK NACHTIGAL

MEMBER


Conflict of Interest Form (coming soon!)